Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 22

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 22
---
 of the three directors Mr. Mangless nominated for election at the 2023 Annual Meeting.

On January 22, 2024, Mr. McFarlane met with Dr. Mickle for dinner to discuss his consulting arrangement with the Company and the status of certain deliverables.

On March 13, 2024, Mr. McFarlane met with Dr. Mickle via teleconference to discuss the consulting arrangement with the Company and the status of certain deliverables. Dr. Mickle expressed support for the Company’s strategic direction and management’s execution. Dr. Mickle also indicated he had no interest in serving as a director unless specifically invited to do so.

On March 22, 2024, Mr. McFarlane, Mr. Clifton, and Mr. Bode met via teleconference with Mr. Elko, Mr. Mangless and Ryan Ball, a stockholder of the Company, to discuss questions raised by Mr. Elko, Mr. Mangless, and Mr. Ball in relation to the Company’s compensation and corporate governance practices.

On April 8, 2024, following requests from Mr. Elko, Mr. Clifton sent an email to Mr. Elko, copying Mr. Mangless, Mr. Ball, Mr. McFarlane, Mr. Clifton, Mr. Bode, and Tamara A. Favorito, a current director, Board Chair, and chair of the audit committee, as well as a nominee recommended by the Board for re-election at the Annual Meeting.

On June 25, 2024, Rahsaan W. Thompson was appointed as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters was appointed as Chief People Officer.

On September 20, 2024, Dr. Mickle received performance-based restricted stock units pursuant to the terms of his consulting arrangement.

On October 23, 2024, Mr. Mangless sent an email to Mr. Bode expressing satisfaction with the Board’s choice of Mr. McFarlane as the Company’s Chief Executive Officer. Mr. Mangless reiterated his previous suggestion that the Company strengthen its relationship with Dr. Mickle to enhance the LAT (Ligand Activated Therapy) platform pipeline and shared suggestions for corporate governance, including declassifying the Board and increasing the diversity of the Board. Mr. Mangless also noted he was in favor of the Board nominating Dr. Mickle to replace Ms. Favorito at the Annual Meeting, should the Board not increase in size.

On or